NTIDC - North Texas Infectious Disease Consultants

02/20/2026

🦠 Exciting news for immunocompromised patients! New in vitro data confirms that Pemgarda (pemivibart) continues to effectively neutralize the dominant SARS-CoV-2 variant XEC, which now accounts for a significant portion of circulating COVID-19 variants in the US. As the virus evolves, Pemgarda's ability to target the stable receptor-binding domain of the spike protein remains a crucial tool for protecting our most vulnerable patients. Read more about how this monoclonal antibody is making a difference. 💉

https://www.contagionlive.com/view/pemgarda-maintains-effectiveness-against-evolving-sars-cov-2-variants

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

01/01/2026

Wishing you and your family a happy and healthy new year!

12/22/2025

Happy Holidays! We wish you and your family a joyful holiday season!

11/27/2025

Wishing you and your family a wonderful Thanksgiving!

11/11/2025

We thank you for your commitment and celebrate your service.

10/24/2025

🎃✨ NTIDC’s 10th Annual Pumpkin Decorating Contest! ✨🎃

What a fang-tastic time we had! 🧡 We had 173 votes and so many creative pumpkins — you all crushed it! 🙌

Big shoutout to everyone who helped plan, decorate, move furniture, and cheer each other on. You make these events so much fun! 💪🎨

🥇 1st Place: Oscar the Grouch — Stephanie Arias
🥈 2nd Place: SpongeBob SquarePants — Laura Rodriguez
🥉 3rd Place: Witchy Pooh — Sal Prieto

Now that the pumpkins are done, we’re ready to bring on the costume contest! 👻🎭

10/06/2025

New research suggests that a biodegradable cabotegravir PrEP implant could protect against HIV for up to a year—and unlike injections, it can be fully removed if needed. This innovation may revolutionize HIV prevention by making protection more convenient and reducing resistance risks.

Read more here: https://www.poz.com/article/cabotegravir-prep-implant-might-prevent-hiv-year #

The removable implant maintained adequate cabotegravir levels for several months in a mouse study without the injectable drug’s “long tail.”

09/18/2025

🎉 𝐃𝐫. 𝐒𝐥𝐨𝐚𝐧’𝐬 𝐁𝐢𝐫𝐭𝐡𝐝𝐚𝐲 𝐁𝐚𝐬𝐡: 𝐍𝐞𝐫𝐟 𝐖𝐚𝐫 𝐄𝐝𝐢𝐭𝐢𝐨𝐧! 🎯

Today we honored the legacy of Dr. Louis Sloan with our annual BIRTHDAY Nerf War, cheese pizza, and yellow cake with chocolate icing—his favorites. 💛

Dr. Sloan was more than a founder of NTIDC—he was a visionary, a healer, and a beloved friend. He joined NTIDC in 1994, became sole owner in 2007, and transformed the practice with groundbreaking HIV/AIDS research, a specialty pharmacy, and a compassionate care model that still guides us today. He passed in 2017 after a courageous battle with lymphoma, but his spirit lives on in every patient we serve and every joyful moment we share.

From saving lives to making us laugh, Dr. Sloan created a culture of care, kindness, and community. Today’s Nerf War is our way of saying: we remember, we celebrate, and we carry your light forward. 💥

Swipe through to see the fun, the food, and the fierce foam battles! 📸

09/15/2025

On 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟗, 𝟐𝟎𝟐𝟓, NTIDC Medical Assistants and Research Team convened at 𝐓𝐡𝐞 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐆𝐫𝐢𝐥𝐥𝐞 𝐢𝐧 𝐃𝐚𝐥𝐥𝐚𝐬 for an exclusive educational dinner featuring 𝐃𝐫. 𝐍𝐚𝐝𝐢𝐚 𝐖𝐢𝐧𝐬𝐭𝐨𝐧, FNP, PhD, AAHIVS, MPH, APRN, Adjunct Assistant Professor at UNT Fort Worth. The evening focused on 𝐂𝐚𝐮𝐬𝐞𝐬 𝐨𝐟 𝐕𝐢𝐫𝐞𝐦𝐢𝐚 𝐚𝐧𝐝 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐭𝐨 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐕𝐢𝐫𝐚𝐥 𝐒𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧, in collaboration with 𝐆𝐢𝐥𝐞𝐚𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬.

We are proud to recognize the 𝐍𝐓𝐈𝐃𝐂 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐓𝐞𝐚𝐦 for their 𝐨𝐮𝐭𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 during a recent 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐚𝐧𝐝 𝐬𝐭𝐮𝐝𝐲 𝐞𝐱𝐭𝐞𝐫𝐧𝐚𝐥 𝐚𝐮𝐝𝐢𝐭 conducted by 𝐌𝐞𝐫𝐜𝐤 on 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟏, 𝟐𝟎𝟐𝟓. Their dedication to excellence continues to set the benchmark in clinical research.

We also extend our sincere appreciation to our 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐀𝐬𝐬𝐢𝐬𝐭𝐚𝐧𝐭𝐬, whose expertise and commitment are vital to the success of our clinical operations and patient care. Their contributions are deeply valued and integral to NTIDC’s continued impact.

Since 2001, NTIDC has conducted hundreds of clinical trials in HIV, PrEP, HCV, C. diff, and antibiotics — consistently exceeding enrollment goals and maintaining a high retention rate. Our long-standing partnerships with 𝐆𝐢𝐥𝐞𝐚𝐝, 𝐌𝐞𝐫𝐜𝐤, and 𝐕𝐢𝐢𝐕 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 have been instrumental in advancing infectious disease care and research. We remain deeply grateful for their continued collaboration and support.

👏 Congratulations to our 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐓𝐞𝐚𝐦, our 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐀𝐬𝐬𝐢𝐬𝐭𝐚𝐧𝐭𝐬, and the 𝐞𝐧𝐭𝐢𝐫𝐞 𝐍𝐓𝐈𝐃𝐂 𝐬𝐭𝐚𝐟𝐟 — truly the best in the business.
Thank you to everyone who contributed to making this evening both meaningful and memorable.

09/11/2025

Remember. Never forget. #911

09/05/2025

📸 Event Recap | ViiV Speaker–Patient Ambassador Program

Grateful to have attended and supported the ViiV Healthcare Speaker–Patient Ambassador Program in Dallas last month, featuring Dr. William Short and an inspiring patient ambassador story that reminded us why we do what we do. 💙

The evening was filled with insightful discussion, connection across disciplines, and a shared commitment to advancing HIV care through education and empathy. Special thanks to Bernadette Calimlim and Joanna from for hosting such a meaningful event.

👏 Shoutout to our amazing team — from MDs and APPs to Pharmacists, Nurses, MAs, and our Research crew — who showed up ready to learn and lead.

Here’s to continuing the conversation and staying patient-centered in everything we do. 🧠💬🌍

📍Truluck’s, Dallas

📅 August 21, 2025

09/03/2025

A new global study reveals that the shingles vaccine may do more than protect against a painful rash—it could also lower the risk of heart attack or stroke by up to 20%.

Researchers found that vaccination was linked to an 18% reduced risk of cardiovascular events in adults, with even greater benefit seen in those over 50. While more research is needed, this adds to growing evidence that vaccines can play a role in protecting overall heart health.
https://www.theguardian.com/society/2025/aug/28/shingles-vaccine-heart-cardiovascular-medical-research

First global systematic review finds vaccine associated with 18% lower risk of stroke or heart attack in adults